Palladio Biosciences
Ron Dadino is the Vice President of CMC and Manufacturing and Head of Quality for Palladio Biosciences. He brings over 35 years of experience in the development and commercialization of pharmaceutical products. Ron has held executive management positions in both large and small companies and has commercialized over 20 products. He has led large global organizations and has negotiated global product regulatory approvals. In addition to his work in product development and technical operations, Ron has led both clinical and commercial manufacturing as well as managing the construction of both laboratory and manufacturing facilities. He has a diverse product background and has brought all major dosage forms to market.
Ron holds a BS in pharmacy from the Philadelphia College of Pharmacy and Science and an MS in Pharmaceutical Quality Assurance from Temple University.
This person is not in any offices
Palladio Biosciences
Palladio Biosciences, Inc., is a Centessa company. Their first product, lixivaptan, is in Phase 3 clinical development for the treatment of autosomal polycystic kidney disease (ADPKD). ADPKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive disease.